SNHG3 and prostate cancer: Additionally, animal models with tumors showed that reducing SNHG3 led to smaller tumor volume and weight, including bladder cancer [6, 7], breast cancer [8, 10, 11], colorectal cancer [15], gastric cancer [18, 19], glioma [21], laryngeal squamous cell carcinoma [23], ovarian cancer [29], papillary thyroid carcinoma [33], and prostate cancer [30] (Table 2).